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Introduction
Pregnant women have been reported to be in a proar-
rhythmic state because of physiologic cardiovascular
changes, including marked increases in stroke volume
and cardiac output, that can become a hemodynamic
burden during pregnancy [1]. Paroxysmal supraven-
tricular tachycardia (PSVT) is one of the most common
cardiac arrhythmias associated with pregnancy [2]. It
can be treated effectively and safely using medical
treatment without adverse effects to the mother or fetus
[3–7]. We present an unusual case of maternal death
and intrauterine fetal demise following medical
treatment of PSVT in late gestation.
Case Report
A 30-year-old, gravida 1, para 0, woman came to the
outpatient clinic of our obstetrics and gynecology
department at 35 weeks of gestation. She had suffered
from palpitations and shortness of breath that lasted 3
days. She denied any history of systemic diseases, but
she did acknowledge not having regular prenatal care
during pregnancy. Immediate electrocardiographic
examination revealed PSVT. She was referred to the
emergency room for further evaluation. She had a heart
rate of 220 beats/min, blood pressure of 101/56 mmHg,
respiratory rate of 20 breaths/min, and body tempera-
ture of 35.9°C. She was not overly distressed. Physical
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examination revealed no thyromegaly, exophthalmos,
or jugular vein distension. Bilateral lungs were clear to
auscultation and percussion. Her extremities showed
no symptoms of pedal edema or cyanosis. The fundal
height of the uterus was consistent with dates. Fetal
heart monitoring revealed a reactive heartbeat of 150
beats/min at baseline.
A single bolus of verapamil (5 mg) was given intra-
venously after the vagal maneuver failed to stop the
PSVT (Figure 1). The first relapse of PSVT occurred after
2 hours, when her heart rate increased to 203 beats/
min. Intravenous adenosine (6 mg) was given
immediately, but a second relapse occurred shortly
afterwards. A higher dose of adenosine (12 mg) was
administered after 5 minutes. The patient’s heart rate
returned to a sinus rhythm within 30 seconds of
administration (Figure 2). An even higher dose of
adenosine (18 mg) was administered after 25 minutes
for a third relapse of PSVT (Figure 3). The patient was
conscious throughout the administration of adenosine
and the entire course of relapses. She lost consciousness
30 minutes after the last dose of adenosine with a
sudden onset of convulsions that lasted 30 seconds,
leading to apnea and shock. The patient exhibited
E1M1V1 symptoms on the Glasgow coma scale as well as
bradycardia with undetectable blood pressure. Despite
immediate administration of advanced cardiac life
support (ACLS), she showed no signs of improvement
and died. Concurrent sonographic examination of the
uterus revealed intrauterine fetal demise during the
ACLS procedure.
Discussion
Hemodynamic fluctuation during pregnancy may lead
to the increased incidence and enhanced severity of
PSVT [2,8]. The primary therapeutic treatment of PSVT
is the vagal maneuver, but failure of this treatment has
forced clinicians to consider a variety of pharmacologic
agents as secondary treatment. Similar approaches are
employed for all patients during this treatment. However,
special attention should be given to drug selection when
treating pregnant women. Drugs that can potentially
affect the fetus should be avoided. Only propranolol (a
`-blocker), verapamil (a calcium channel blocker), and
adenosine are approved for PSVT by the US Food and
Drug Administration. Adenosine is the most effective
drug and has the fewest side effects in pregnant women
with PSVT. Propranolol therapy is not only harmful to
the fetus, it is also not as effective as verapamil and
adenosine in the treatment of PSVT [9]. Although
verapamil is as effective as adenosine, its potential side
effects include hypotension, bradycardia, and congestive
heart failure [3]. The minor side effects of adenosine
include facial flushing, dyspnea, chest discomfort, and
short-lived arrhythmias [3–7]. Some authors have
reported other major sequelae, including syncope,
convulsion, cardiac arrest, and shock [10–13]. The
manufacturer recommends an initial intravenous
administration of a bolus of adenosine, of 6 mg. If this
is unsuccessful, the manufacturer recommends a second
Figure 3. The third relapse of paroxysmal supraventricular
tachycardia.
Figure 1. Paroxysmal supraventricular tachycardia after
treatment with vagal maneuver.
Figure 2. Sinus rhythm after treatment with adenosine 12 mg.
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dose of adenosine of 12 mg, but no larger doses [14].
When either drug (verapamil or adenosine) fails or
induces shock, the clinician is forced to consider syn-
chronized electrical cardioversion as tertiary treatment,
the last alternative available for the treatment of PSVT
[13].
The present report is of a case of PSVT in a pregnant
woman in late gestation. The initial administration of
verapamil (5 mg) failed to cure the PSVT. Administration
of a high dose of adenosine (36 mg) was required to
prevent the relapse of PSVT. However, the patient lost
consciousness after the third high dose of adenosine,
which led to apnea, convulsion, and shock. Despite
immediate use of ACLS, the patient showed no signs of
improvement and died. Concurrent sonographic
examination of the uterus revealed intrauterine fetal
demise during ACLS.
The cause of death in this case is still unclear. PSVT
in late gestation can be associated with maternal death
even following conversion to sinus rhythm using medical
treatment. Numerous actions can lead to secondary
seizure. Apnea resulting in hypoxemia is the most
plausible explanation, because it triggers PSVT into
convulsion and shock. The association between high-
dose adenosine and shock remains doubtful. Autopsy
was not approved by her family members. The patient
could have died as a result of other undetermined
diseases. We believe that a high dose of adenosine may
be required to prevent the relapse of PSVT in pregnant
women in late gestation. However, clinical use of
adenosine for PSVT should alert the clinician to consider
the potential risks of administering high-dose adenosine
in pregnant women. Administration of a higher dose of
adenosine was, in our opinion, partially responsible for
the maternal death and intrauterine fetal demise in this
case.
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